Table 4.
Unadjusted and adjusted cumulative mean quality-adjusted life years (QALYs) from baseline.
| Time point | Cisplatin |
Cetuximab |
Mean difference (95% CI) | P-value t-test | ||
|---|---|---|---|---|---|---|
| No· Dead | Mean (SE) | No· Dead | Mean (SE) | |||
| 4a: Unadjusted | ||||||
| End of treatment | 0 | 0·120 (0·002) | 1 | 0·114 (0·002) | −0·006 (−0·012 to 0·000) | 0·058 |
| 3 months post treatment | 1 | 0·294 (0·005) | 2 | 0·278 (0·005) | −0·016 (−0·031 to −0·001) | 0·031 |
| 6 months post treatment | 3 | 0·494 (0·008) | 5 | 0·466 (0·008) | −0·028 (−0·05 to −0·007) | 0·011 |
| 12 months post treatment | 4 | 0·904 (0·014) | 7 | 0·849 (0·015) | −0·055 (−0·095 to −0·015) | 0·007 |
| 24 months post treatment | 4 | 1·740 (0·027) | 17 | 1·612 (0·033) | −0·128 (−0·212 to −0·044) | 0·003 |
| 4b: Adjusted | ||||||
| End of treatment | −0·003 (−0·008 to 0·001) | 0·168 | ||||
| 3 months post treatment | −0·012 (−0·025 to 0·002) | 0·083 | ||||
| 6 months post treatment | −0·021 (−0·041 to −0·002) | 0·030 | ||||
| 12 months post treatment | −0·044 (−0·080 to −0·007) | 0·020 | ||||
| 24 months post treatment | −0·107 (−0·186 to −0·029) | 0·007 | ||||